scholarly journals P01.12 Brain Necrosis in Patients With Metastatic Lung and Breast Cancer Successfully Treated With Bevacizumab

2021 ◽  
Vol 16 (3) ◽  
pp. S241
Author(s):  
L. Raez ◽  
A. Botero ◽  
A. Khan ◽  
P. Izquierdo ◽  
I. Castellon
Keyword(s):  
Breast Cancer ◽  
Brain Necrosis ◽  
Metastatic Lung

scholarly journals Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

2021 ◽  
Author(s):  
Luis E. Raez ◽  
Kathleen Danenberg ◽  
Daniel Sumarriva ◽  
Joshua Usher ◽  
Jacob Sands ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Response To Therapy ◽  
Liquid Biopsies ◽  
Blood Samples ◽  
Lung Cancers ◽  
Metastatic Lung ◽  
Clinical Responses ◽  
Pre Treatment ◽  
Actin Expression

Aim: We report an exploratory analysis of cfRNA as a biomarker to monitor clinical responses in non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer (CRC). An analysis of cfRNA as a method for measuring PD-L1 expression with comparison to clinical responses was also performed in the NSCLC cohort. Methods: Blood samples were collected from 127 patients with metastatic disease that were undergoing therapy, 52 with NSCLC, 50 with breast cancer, and 25 with CRC. cfRNA was purified from fractionated plasma, and following reverse transcription (RT), total cfRNA and gene expression of PD-L1were analyzed by real-time polymerase chain reaction (qPCR) using beta-actin expression as a surrogate for relative amounts of cfDNA and cfRNA. For the concordance study of liquid biopsies and tissue biopsies, the isolated RNA was analyzed by RNAseq for the expressions of 13 genes. We had to close the study early due to a lack of follow-up during the Covid-19 pandemic. Results: We collected a total of 373 blood samples. Mean cfRNA PCR signals after RT were about 50-fold higher than those of cfDNA. cfRNA was detected in all patients, while cfDNA was detected in 88% of them. A high concordance was found for the expression levels of 13 genes between blood and solid tumor tissue. Changes in cfRNA levels followed over the course of treatments were associated with response to therapy, increasing in progressive disease (PD) and falling when a partial response (PR) occurred. The expression of PD-L1 over time in patients treated with immunotherapy decreased with PR but increased with PD. Pre-treatment levels of PD-L1 were predictive of response in patients treated with immunotherapy. Conclusion: Changes in cfRNA correlate with clinical response to the therapy. Total cfRNA may be useful in predicting clinical outcomes. PD-L1 gene expression may provide a biomarker to predict response to PD-L1 inhibition.

scholarly journals Metabonomic analysis of metastatic lung tissue in breast cancer mice by an integrated NMR-based metabonomics approach

RSC Advances ◽  
2017 ◽  
Vol 7 (45) ◽  
pp. 28001-28008 ◽  
Author(s):  
Yongxia Yang ◽  
Jingli Zhang ◽  
Ying Liu ◽  
Binglin Li ◽  
Jiangchao Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Metastasis ◽  
Lung Tissue ◽  
Metastatic Lung ◽  
The Common ◽  
Potential Biomarkers

This study identified the common potential biomarkers for early lung metastasis of breast cancer in two models.

scholarly journals Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Helmneh M Sineshaw ◽  
Ahmedin Jemal ◽  
Kimmie Ng ◽  
Raymond U Osarogiagbon ◽  
K Robin Yabroff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Patients ◽  
De Novo ◽  
Metastatic Cancer ◽  
Treatment Patterns ◽  
Cancer Type ◽  
Cancer Centers ◽  
Lung Cancer Patients ◽  
Metastatic Lung

Abstract Background Little is known about patterns of and factors associated with treatment for de novo metastatic cancer patients who die soon after diagnosis. In this study, we examine treatment patterns for patients newly diagnosed with metastatic lung, colorectal, breast, or pancreatic cancer who died within 1 month of diagnosis. Methods We identified 100 848 adult patients in the National Cancer Database with de novo metastatic lung, colorectal, breast, and pancreatic cancer, diagnosed between 2004 and 2014 and who died within 1 month. We performed descriptive and multivariable logistic regression analyses to examine receipt of surgery, chemotherapy, radiation, and hormonal therapy by cancer type, adjusting for sociodemographic and clinical variables. Results Treatment substantially varied by cancer type, over time, age, insurance, and facility type. Surgery ranged from 0.4% in pancreatic to 28.3% in colorectal cancer (CRC) patients, chemotherapy from 5.8% among CRC to 11% in lung and breast cancer patients, and radiotherapy from 1.3% in pancreatic to 18.7% in lung cancer patients. Use of some treatments (eg, surgery for CRC and breast cancer) progressively declined between 2004 and 2014. Compared with lung cancer patients treated at National Cancer Institute-designated cancer centers, those treated at community cancer centers had 48% lower odds of radiation. Conclusions Treatment of patients diagnosed with imminently fatal de novo metastatic cancer varied markedly by cancer type and patient/facility characteristics. These variations warrant more research to better identify patients with imminently fatal de novo metastatic cancer who may not benefit from aggressive and expensive therapies.

scholarly journals A Rare Case of Metastatic Lung Cancer that Needed to be Differentiated from Inflammatory Breast Cancer

2015 ◽  
Vol 76 (11) ◽  
pp. 2654-2659
Author(s):  
Kazuki HASHIMOTO ◽  
Eri HOHOKABE ◽  
Yuichiro KIKAWA ◽  
Ryosuke MATSUOKA ◽  
Yukihiro IMAI
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Inflammatory Breast Cancer ◽  
Rare Case ◽  
Metastatic Lung Cancer ◽  
Metastatic Lung

scholarly journals A Case of Brain Necrosis after Stereotactic Irradiation for Brain Metastasis of Breast Cancer Treated with Bevacizumab

2021 ◽  
Vol 82 (2) ◽  
pp. 367-372
Author(s):  
Junna SAKANE ◽  
Toshihiro KOBAYASHI ◽  
Masako HIRAMATSU ◽  
Ichiro TSUNEMATSU ◽  
Maiko SANFORD ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Stereotactic Irradiation ◽  
Brain Necrosis

scholarly journals Severe Hyperkalemia and Bilateral Adrenal Metastasis

2009 ◽  
Vol 2009 ◽  
pp. 1-2 ◽  
Author(s):  
Michael Nagler ◽  
Beat Müller ◽  
Verena Briner ◽  
Ralph Winterhalder
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Clinical Symptoms ◽  
Adrenal Metastasis ◽  
Common Finding ◽  
Metastatic Lung Cancer ◽  
Adrenal Metastases ◽  
Metastatic Lung ◽  
Severe Hyperkalemia

Adrenal metastases are a common finding in metastatic lung and breast cancer. Often there are no clinical symptoms suggesting them. In this paper, we present a case of a 66-year-old man with metastatic lung cancer suffering from severe hyperkaliemia due to hypoaldosteronism as a result of bilateral adrenal metastasis.

Health state utility and toxicities in metastatic lung cancer: A qualitative study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16017-16017
Author(s):  
B. Nafees ◽  
M. Stafford ◽  
S. Bhalla ◽  
J. Watkins
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Stable Disease ◽  
Progressive Disease ◽  
Response To Therapy ◽  
Economic Evaluations ◽  
Health State ◽  
Metastatic Lung Cancer ◽  
Health States ◽  
Metastatic Lung

16017 Background: In metastatic lung cancer, it is expected that quality of life is impacted both by the efficacy and toxicity of therapy. Previous research has reported health states either based on response to therapy or on toxicity, but not in combination. Using methodology applied in breast cancer (Narewska 2005), we developed health state descriptions for advanced non-small cell lung cancer (NSCLC) for use in cost-utility analyses. Methods: An interview discussion and content validation guide was produced based on literature review and clinical input. Response to therapy was described as responding disease, stable disease, or progressive disease. The most common toxicities were selected based on randomized clinical trials. Descriptions of health states were reviewed by clinical specialists. Final health states will be piloted and then used in a societal-based valuation study using standard gamble technique. The contributory effect of disease state and toxicity will be estimated using a mixed model analysis and compared with the data from the previous breast cancer utility study. Results: Eight toxicities were identified: alopecia and grade 3/4 neutropenia, febrile neutropenia, hand-foot syndrome, gastrointestinal (diarrhea/vomiting), rash, stomatitis and fatigue. These were combined with response to therapy to yield 19 health states: 9 responding disease (one with each toxicity plus one with no toxicity), 9 stable disease (one with each toxicity plus one with no toxicity) and one progressive disease (toxicity not included). These health states were reviewed by 6 pulmonary oncologists and 3 specialist nurses. Conclusions: Development of health states that combine both efficacy and toxicity will be useful in evaluating the relative value of therapies for advanced NSCLC and comparison with other diseases. Input by clinical experts has provided validation for the proposed health states. Evaluation of these health states by members of society will provide appropriate perspective for economic evaluations. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document